Business Description
PepGen Inc
NAICS : 325412
SIC : 2834
ISIN : US7133171055
Total Employee Number:
59Description
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.99 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.22 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 21.5 | |||||
3-Year EPS without NRI Growth Rate | 21.7 | |||||
3-Year FCF Growth Rate | 21.6 | |||||
3-Year Book Growth Rate | -34.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 17.44 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 84.78 | |||||
9-Day RSI | 77.85 | |||||
14-Day RSI | 69.51 | |||||
3-1 Month Momentum % | -15.57 | |||||
6-1 Month Momentum % | -80.28 | |||||
12-1 Month Momentum % | 27.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.98 | |||||
Quick Ratio | 14.98 | |||||
Cash Ratio | 14.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -42.7 | |||||
Shareholder Yield % | 0.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -63.55 | |||||
ROA % | -51.48 | |||||
ROIC % | -272.12 | |||||
3-Year ROIIC % | 295.83 | |||||
ROC (Joel Greenblatt) % | -368.58 | |||||
ROCE % | -59.83 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.06 | |||||
Price-to-Tangible-Book | 1.06 | |||||
EV-to-EBIT | -0.32 | |||||
EV-to-EBITDA | -0.34 | |||||
EV-to-Forward-Revenue | 16.33 | |||||
EV-to-FCF | -0.34 | |||||
| Price-to-Net-Current-Asset-Value | 1.27 | |||||
| Price-to-Net-Cash | 1.29 | |||||
Earnings Yield (Greenblatt) % | -312.5 | |||||
FCF Yield % | -54.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PEPG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PepGen Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.75 | ||
| Beta | 2.4485 | ||
| 3-Year Sharpe Ratio | 0.38 | ||
| 3-Year Sortino Ratio | 1.04 | ||
| Volatility % | 315.54 | ||
| 14-Day RSI | 69.51 | ||
| 14-Day ATR ($) | 0.133095 | ||
| 20-Day SMA ($) | 1.68125 | ||
| 12-1 Month Momentum % | 27.03 | ||
| 52-Week Range ($) | 1.01 - 7.8 | ||
| Shares Outstanding (Mil) | 69.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PepGen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PepGen Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 30 days | ||
| General meeting for 2026 | 2026-06-18 12:00 | 1.70 (+5.59%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 1.70 (-4.49%) | ||
| FREEDOM2-DM1 5 mg/kg Clinical Data Update | 2026-03-30 16:30 | 4.52 (-7.00%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 15:00 | 5.57 (-0.89%) | ||
| Annual report for 2025 | 2026-03-04 | 6.42 (+1.58%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-04 | 6.42 (+1.58%) | ||
| Guidance call for 2025 | 2025-11-13 16:00 | 5.13 (+9.15%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 4.65 (+9.41%) |
Show
Entries
PepGen Inc Frequently Asked Questions
What is PepGen Inc(PEPG)'s stock price today?
The current price of PEPG is $2.06. The 52 week high of PEPG is $7.80 and 52 week low is $1.01.
When is next earnings date of PepGen Inc(PEPG)?
The next earnings date of PepGen Inc(PEPG) is 2026-08-07 Est..
Does PepGen Inc(PEPG) pay dividends? If so, how much?
PepGen Inc(PEPG) does not pay dividend.
Guru Commentaries on NAS:PEPG
No articles.
Press Release
Articles on PepGen Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers